Icrucumab, an novel monoclonal protein, is presently undergoing thorough clinical evaluation for its application in various inflammatory conditions. Preliminary studies suggest a promising mechanism of effect, selectively blocking the impact of IL-17, a key cytokine associated in autoimmune react

Osocimab, formerly known as BAY 1213790, represents a groundbreaking monoclonal immunoglobulin currently experiencing clinical evaluation for the management of multiple hematologic cancers. This molecule selectively targets CD38, a membrane receptor present on abnormal cells in conditions like mu